Successful management of an ABO-mismatched lung allograft using antigen-specific immunoadsorption, complement inhibition, and immunomodulatory therapy

• Published in: Transplantation Vol. 74; no. 1; p. 79
• Main Authors: Pierson, 3rd, Richard N, Loyd, James E, Goodwin, Andrea, Majors, Dan, Dummer, J Stephen, Mohacsi, Paul, Wheeler, Alistair, Bovin, Nicolai, Miller, Geraldine G, Olson, Sandy, Johnson, Joyce, Rieben, Robert, Azimzadeh, Agnes
• Format: Journal Article
• Language: English
• Published: United States 15.07.2002
• Subjects: ABO Blood-Group System; Aged; Anti-Inflammatory Agents - administration & dosage; Antilymphocyte Serum - administration & dosage; Blood Group Incompatibility - immunology; Blood Group Incompatibility - therapy; Complement System Proteins - immunology; Cyclophosphamide - administration & dosage; Cyclosporine - administration & dosage; Graft Survival - immunology; Humans; Immunosorbent Techniques; Immunosuppression - methods; Immunosuppressive Agents - administration & dosage; Lung Transplantation - immunology; Male; Mycophenolic Acid - administration & dosage; Mycophenolic Acid - analogs & derivatives; Prednisone - administration & dosage; Transplantation, Homologous
• ISSN: 0041-1337
• DOI: 10.1097/00007890-200207150-00014

Successful management of an ABO-mismatched lung allograft recipient has not previously been described. Because of a clerical error, a 67-year-old blood type B patient with idiopathic pulmonary fibrosis received a left single-lung allograft from a blood type A donor. Cyclophosphamide was added to immunosuppression with anti-thymocyte globulin induction, cyclosporine, mycophenolate mofetil, and prednisone. When increasing anti-A antibody titers were detected, antigen-specific immunoadsorption, anti-CD20 monoclonal antibody, and recombinant soluble complement receptor type 1 (TP10) were administered. Rising anti-A antibody titers were reduced acutely by immunoadsorption, and remained low during long-term follow-up. Humoral injury to the graft was not detected. Acute cellular rejection and multiple complications were successfully managed. Three years after transplantation the patient is clinically well on stable maintenance immunosuppression and prophylactic photochemotherapy. Modulation of anti-A antibody, preserved graft function, and a favorable patient outcome can be achieved for an ABO-mismatched lung allograft.